First experience of topical SDZ ASM 981 in children with atopic dermatitis

British Journal of Dermatology

Volumn 144, Issue 4, 2001, Pages 781-787

  Harper, J ^a   Green, A ^a   Scott, G ^b   Gruendl, E ^b   Dorobek, B ^b   Cardno, M ^c   Burtin, P ^b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Novartis Research Centre   (United Kingdom)

Author keywords

Atopic dermatitis; Child; Pharmacokinetics; SDZ ASM 981; Topical

Indexed keywords

PIMECROLIMUS;

AREA UNDER THE CURVE; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CREAM; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL;

ADMINISTRATION, CUTANEOUS; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; MALE; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 0035034382     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2001.04133.x     Document Type: Article

References (9)

1. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology
2. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology
3. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis
4. SDZ ASM 981 cream: An emerging new drug for the treatment of atopic dermatitis
5. Low systemic concentrations of SDZ ASM 981 after topical treatment of extensive atopic dermatitis lesions
6. Potential hazards of topical steroids therapy
7. Diagnostic features of atopic dermatitis
8. The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis
9. Oral SDZ ASM 981: Safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis